<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CLOPIDOGREL BISULFATE <img border="0" src="../images/pr.gif"/></span><br/>(clo-pi'do-grel)<br/><span class="topboxtradename">Plavix<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antiplatelet agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits platelet aggregation by selectively preventing the binding of adenosine diphosphate to its platelet receptor. It
         is an analog of ticlopidine. The drug's effect on the adenosine diphosphate receptor of a platelet is irreversible.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Consequently, clopidrogrel prolongs bleeding time.</p>
<h1><a name="uses">Uses</a></h1>
<p>Secondary prevention of MI, stroke, and vascular death in patients with recent MI, stroke, unstable angina or established
         peripheral arterial disease.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Reduction of restenosis after stent placement.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to clopidogrel; intracranial hemorrhage, peptic ulcer, or any other active pathologic bleeding; pregnancy
         (category B). Discontinue clopidogrel 7 d before surgery and during lactation. Safety and efficacy not established in children.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent use with drugs that might induce gastrointestinal bleeding; GI bleeding; hepatic impairment (moderate to severe);
         patients at risk for increased bleeding.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Secondary Prevention</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not administer to persons with active pathologic bleeding.</li>
<li>Discontinue drug 7 d prior to surgery.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flu-like syndrome, fatigue, pain, arthralgia, back pain. <span class="typehead">CV:</span> Chest pain, edema, hypertension, thrombocytic purpura. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, diarrhea, nausea, hypercholesterolemia.  <span class="typehead">Hematologic:</span> Thrombotic thrombocytopenic purpura, epistaxis. <span class="typehead">CNS:</span> Headache, dizziness, depression. <span class="typehead">Respiratory:</span> URI, dyspnea, rhinitis, bronchitis, cough. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">nsaids</span> may increase risk of bleeding events. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>garlic,</b>
<b>ginger,</b>
<b>ginkgo</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> 2 h; reaches steady state in 37 d. <span class="typehead">Distribution:</span> 9498% protein bound. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed in plasma to active metabolite. <span class="typehead">Elimination:</span> 50% excreted in urine and 50% in feces. <span class="typehead">Half-Life:</span> 8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Carefully monitor for and immediately report S&amp;S of GI bleeding, especially when coadministered with <small>NSAID</small>s, aspirin, heparin, or warfarin.
         </li>
<li>Lab tests: Periodic platelet count and lipid profile.</li>
<li>Evaluate patients with unexplained fever or infection for myelotoxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any unusual bleeding (e.g., black, tarry stools).</li>
<li>Avoid chronic aspirin or <small>NSAID</small> use unless approved by physician.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>